MIT spinout SiTration and BHP, the world’s largest copper producer, have launched two pilots at the historic Copper Cities site in Arizona to test copper recovery technology. The mine produced nearly 400,000 tonnes of copper between the 1950s and the early 1980s. The projects aim to use existing resources to strengthen domestic supply chains while producing copper at the bottom of the global cost curve. Global copper demand is projected to rise by around 70% by 2050, driven by energy infrastructure and data-center buildouts.

Odysight.ai said it priced a public offering of 3,437,500 common shares at $3.20 per share. The company expects gross proceeds of about $11 million before underwriting discounts, commissions and offering expenses. Roth Capital Partners has a 30-day option to buy up to an additional 515,625 shares under an over-allotment option.

Edesa Biotech said it has priced an underwritten public offering of 3,870,500 common shares together with accompanying warrants, at a combined price of $5.50 per share. Certain investors may instead purchase prefunded warrants for up to 675,000 shares, with each prefunded warrant exercisable at $0.0001. Each common share or prefunded warrant is sold with an accompanying warrant.

Ascentage Pharma reported unaudited results for the first half of 2026, with revenue up 29% year over year to US$44.5 million, driven mainly by higher Olverembatinib sales. As of June 30, 2026, Olverembatinib had been added to formularies at 879 DTP pharmacies and hospitals. Hospital coverage rose 34% year over year to 394 hospitals.

WeTouch Technology reported results for the first half of fiscal year 2026, with total revenue of $30.3 million, up 9.4% year over year. Net income rose 25.5% to $6.0 million, and basic and diluted earnings per share increased to $0.50 from $0.40. Gross margin edged up to 35.3%, while operating cash flow increased to $5.5 million.

H World Group released its unaudited results for the second quarter of 2026, reporting hotel turnover of RMB30.5 billion, up 13.2% year over year. Turnover in China rose 15.3%, while the international segment declined 9.4%. Total revenue increased 10.8% to RMB7.1 billion, and manachised and franchised revenue climbed 25.2% to RMB3.6 billion. Non-GAAP EBITDA came in at RMB2.6 billion versus RMB2.5 billion a year earlier.

Daré Bioscience priced a registered direct offering at $1.37 per share, covering 4,379,581 shares of common stock or prefunded warrants. The company said the deal is structured as an at-the-market offering under Nasdaq rules, with prefunded warrants carrying a $0.0001 per-share exercise price. Gross proceeds at closing are expected to be about $6.0 million before fees and expenses.

GT Capital reported first-half net income of P16.41 billion, down 11% year on year, as revenue fell 15% to P115.4 billion. The company said a slower economy, high inflation and softer vehicle demand weighed on results, with second-quarter growth slowing to 2.3%. Net interest income rose 12.8% and gross loans expanded 12.4%, but automotive net income fell to P8.4 billion from P12.5 billion.

SurgePays reported second-quarter 2026 revenue of $16.20 million, up 40.7% from a year earlier, and net income of $1.29 million. Earnings per share were $0.05. For the first half of 2026, revenue rose 45.7% to $32.19 million, while G&A declined 9.3%. CEO Brian Cox said the company returned to GAAP profitability under a new multichannel revenue structure and that operating income improved by $10.3 million year over year.